Drawing for CAMP4

USPTO serial 97767968

CAMP4

Reviewed by CopyMark Law Group

Reg. 8078909Status 700Registered
Filing date
Status date
Registration date
Dec 23, 2025
Examiner
GAINES, LEAH R
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with CAMP4?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Christina M. Licursi

Christina M. Licursi WOLF, GREENFIELD & SACKS, P.C.600 ATLANTIC AVENUEBOSTON, MA 02210United States

Goods and services

ClassDescriptionStatusFirst use
001Biological and chemical agents, namely, chemical preparations for scientific and research use; synthetic nucleic acids other than for medical or veterinary purposes; chemically modified nucleic acids, other than for medical or veterinary purposes; chemicals for use in biotherapeutics in the biochemical and chemical industries and excluding medical and veterinary purpose; biological preparations for use in industry and science; chemical agents, namely, chemical preparations for analyses in laboratories, other than for medical or veterinary purposesACTIVEJan 22, 2025
005Pharmaceutical, therapeutic pharmaceuticals, and biopharmaceutical preparations and agents for the treatment of a variety of human and animal diseases and disorders, namely, enzyme deficiency diseases and disorders, genetic diseases and disorders, hepatic diseases and disorders, metabolic diseases and disorders, neurological diseases and disorders, neuromuscular diseases and disorders, and rare diseases and disorders; nucleic acid-based therapeutic pharmaceuticals and therapeutic agents for the treatment of a variety of human and animal diseases and disorders, namely, enzyme deficiency diseases and disorders, genetic diseases and disorders, hepatic diseases and disorders, metabolic diseases and disorders, neurological diseases and disorders, neuromuscular diseases and disorders, and rare diseases and disorders; chemicals for use in therapeutic product development and manufacturing processes in the medical fieldACTIVEJan 22, 2025
042Research and development of pharmaceutical, therapeutic and biopharmaceutical preparations and agents for the treatment of a variety of human and animal diseases and disorders, namely, enzyme deficiency diseases and disorders, genetic diseases and disorders, hepatic diseases and disorders, metabolic diseases and disorders, neurological diseases and disorders, neuromuscular diseases and disorders, and rare diseases and disorders; research and development of technology in the field of pharmaceutical, therapeutic and biopharmaceutical preparations and agents; pharmaceutical drug development and drug discovery services; pharmaceutical research and analysis services using machine learning analytics relating to pharmaceutical drug development; scientific research, pharmaceutical research, medical research, technical consultation, and product development for others in the field of biotechnology and development of pharmaceutical, therapeutic, and biopharmaceutical preparations and agentsACTIVEDec 26, 2019

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Dec 23, 2025NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Dec 23, 2025R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Dec 3, 2025SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Dec 3, 2025CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Oct 18, 2025SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Oct 18, 2025AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
May 14, 2025IUAFUSE AMENDMENT FILED—
May 14, 2025EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Nov 6, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Nov 6, 2024EX1GSOU EXTENSION 1 GRANTED—
Nov 6, 2024EXT1SOU EXTENSION 1 FILED—
Nov 6, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
May 14, 2024NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Mar 19, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 19, 2024PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 28, 2024NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Feb 28, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Feb 13, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 13, 2024XAECEXAMINER'S AMENDMENT ENTERED—
Feb 13, 2024GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Feb 13, 2024GNEAEXAMINERS AMENDMENT E-MAILED—
Feb 13, 2024CNEAEXAMINERS AMENDMENT -WRITTEN—
Feb 6, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 5, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 5, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 15, 2023GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 15, 2023GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 15, 2023CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 23, 2023DOCKASSIGNED TO EXAMINER—
Feb 14, 2023NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 28, 2023NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance